IVD Medical Holding Valuation

Q: What is the Fair Price of 1931 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

1931 (HK$1.8) is trading above our estimate of [[fair value]] (HK$0.13)

Is 1931 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1931 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1931 (HK$1.8) is trading above our estimate of fair value (HK$0.13)

Significantly Below Fair Value: 1931 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1931?

Key metric: As 1931 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 1931. This is calculated by dividing 1931's market cap by their current earnings.
What is 1931's PE Ratio?
PE Ratio	10.5x
Earnings	CN¥260.44m
Market Cap	CN¥2.72b

1931 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.6x
Enterprise Value/EBITDA	4.7x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 1931's PE Ratio compare to its peers?

The above table shows the PE ratio for 1931 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	12.9x
3390 Tycoon Group Holdings	12.3x	n/a	HK$2.8b
1345 Shanghai Pioneer Holding	13.9x	n/a	HK$2.4b
2289 Charmacy Pharmaceutical	18x	n/a	HK$1.0b
6833 Sinco Pharmaceuticals Holdings	7.4x	n/a	HK$370.0m
1931 IVD Medical Holding	10.5x	n/a	HK$2.9b

Price-To-Earnings vs Peers: 1931 is good value based on its Price-To-Earnings Ratio (10.5x) compared to the peer average (12.9x).

Price to Earnings Ratio vs Industry

How does 1931's PE Ratio compare vs other companies in the HK Healthcare Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap
574 Pa Shun International Holdings	1.8x	n/a	US$8.15m

No more companies available in this PE range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 1931 is good value based on its Price-To-Earnings Ratio (10.5x) compared to the Hong Kong Healthcare industry average (13x).

Price to Earnings Ratio vs Fair Ratio

What is 1931's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1931 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	10.5x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 1931's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sinopharm Group

HK$62.6b

Engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China.

1099

HK$20.05

-0.7%

0.3%

OrbusNeich Medical Group Holdings

HK$3.4b

An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.

6929

HK$4.10

-5.7%

-48.6%

Hygeia Healthcare Holdings

HK$10.2b

Offers oncology healthcare services in the People's Republic of China.

6078

HK$16.40

-6.6%

-66.9%